Related Experiment Video
Updated: Aug 6, 2026
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Metabolomics Reveals Potential Biomarkers for Early Detection of irAEs in ICI-Treated Patients
Weibin Fan1,2, Haoqun Ma1,3, Yue Zhang1,2
1Department of Pharmacy, Changxing People's Hospital, Huzhou, Zhejiang, People's Republic of China.
Purpose:
To identify predictive metabolic biomarkers for immune-related adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICIs) using metabolomics, supporting early detection and intervention.
Patients And Methods:
Fifty-five ICI-treated cancer patients from Changxing People's Hospital were divided into irAEs-positive (34 cases) and irAEs-negative (21 cases) groups after 12-month follow-up. Pretreatment serum samples were analyzed by untargeted UPLC-MS metabolomics. PCA, OPLS-DA, and KEGG pathway enrichment were used to screen differential metabolites and key pathways.
Results:
Seventy significant differential metabolites (eg, ursodeoxycholic acid, uric acid) were identified. β-Alanine metabolism, pentose phosphate pathway, and coenzyme A biosynthesis were closely correlated with irAEs. Five metabolites showed AUC 0.7-0.9 with favorable predictive performance.
Conclusion:
Metabolomics reveals specific metabolites and metabolic pathways linked to ICI-induced irAEs, providing potential biomarkers for early prediction and new insights into irAEs pathogenesis to optimize clinical management.
